Condorelli M, Bonaduce A, Montemurro A, Mattioli G, Cappello C, Caponnetto S, Terrachini V, Canale C, Varricchio M, Cacciapuoti F
Istituto di Clinica Medica, II Policlinico, Università di Napoli, Italy.
J Cardiovasc Pharmacol. 1989;14 Suppl 8:S83-92.
This randomized, double-blind, placebo-controlled, multicenter trial compared the effects of treatment with ibopamine with those of placebo in patients with severe heart failure who still showed symptoms although they were receiving standard therapy with digitalis and diuretics. The results showed a significant and sustained improvement in exercise tolerance (+70% about in average), clinical condition, and NYHA functional class and a decrease in cardiothoracic ratio and left ventricular end-systolic wall stress in patients treated with ibopamine, digitalis, and diuretics (group 1) compared with patients treated with digitalis, diuretics, and placebo (group 2).
这项随机、双盲、安慰剂对照、多中心试验比较了异波帕胺与安慰剂对重度心力衰竭患者的治疗效果。这些患者尽管接受了洋地黄和利尿剂的标准治疗,但仍有症状。结果显示,与接受洋地黄、利尿剂和安慰剂治疗的患者(第2组)相比,接受异波帕胺、洋地黄和利尿剂治疗的患者(第1组)在运动耐量(平均提高约70%)、临床状况、纽约心脏协会(NYHA)心功能分级方面有显著且持续的改善,心胸比率和左心室收缩末期壁应力降低。